Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study Article

publication date

  • December 21, 2023

webpage

published in

keywords

  • PSA response
  • advanced prostate cancer
  • apalutamide
  • castration resistance
  • deep PSA decline
  • metastatic castration-sensitive prostate cancer
  • overall survival
  • plain language summary
  • radiographic progression-free survival
  • undetectable PSA

start page

  • 563

end page

  • 578

volume

  • 20

issue

  • 10